Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) Director Dennis Podlesak sold 11,975 shares of Syndax Pharmaceuticals stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $23.43, for a total value of $280,574.25. Following the completion of the sale, the director now directly owns 75,763 shares in the company, valued at $1,775,127.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Syndax Pharmaceuticals Trading Down 5.8 %
Shares of NASDAQ SNDX opened at $23.14 on Friday. The business’s 50 day moving average is $22.52 and its two-hundred day moving average is $18.89. The company has a debt-to-equity ratio of 0.04, a current ratio of 12.69 and a quick ratio of 12.69. Syndax Pharmaceuticals, Inc. has a 1-year low of $13.27 and a 1-year high of $25.71. The stock has a market capitalization of $1.31 billion, a P/E ratio of 144.63 and a beta of 1.24.
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) last announced its earnings results on Monday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.03. Syndax Pharmaceuticals had a return on equity of 0.24% and a net margin of 17.84%. As a group, research analysts expect that Syndax Pharmaceuticals, Inc. will post -2.66 EPS for the current year.
Analyst Ratings Changes
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of SNDX. Bank of America Corp DE boosted its position in shares of Syndax Pharmaceuticals by 109.5% during the fourth quarter. Bank of America Corp DE now owns 188,937 shares of the company’s stock valued at $4,135,000 after buying an additional 98,760 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Syndax Pharmaceuticals by 22.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 793,700 shares of the company’s stock valued at $17,374,000 after buying an additional 145,674 shares during the period. BNP Paribas Arbitrage SA boosted its position in shares of Syndax Pharmaceuticals by 544.1% during the fourth quarter. BNP Paribas Arbitrage SA now owns 68,399 shares of the company’s stock valued at $1,497,000 after buying an additional 57,779 shares during the period. Citigroup Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 140.6% in the fourth quarter. Citigroup Inc. now owns 130,087 shares of the company’s stock valued at $2,848,000 after purchasing an additional 76,023 shares during the period. Finally, Allianz Asset Management GmbH purchased a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at approximately $1,624,000. Hedge funds and other institutional investors own 97.81% of the company’s stock.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).
- Get a free copy of the StockNews.com research report on Syndax Pharmaceuticals (SNDX)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.